Compare WSE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSE | ABVX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 11.9B |
| IPO Year | 2025 | 2022 |
| Metric | WSE | ABVX |
|---|---|---|
| Price | $11.74 | $88.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $16.94 | ★ $164.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 10-15-2026 | 09-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.59 | N/A |
| Revenue Next Year | $18.09 | $1,854.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.78 | $69.81 |
| 52 Week High | $13.66 | $148.83 |
| Indicator | WSE | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 30.21 |
| Support Level | $11.22 | $74.79 |
| Resistance Level | $13.23 | $130.28 |
| Average True Range (ATR) | 0.27 | 4.21 |
| MACD | 0.03 | -0.68 |
| Stochastic Oscillator | 83.95 | 1.21 |
Wise is a currency conversion platform that matches, where possible, offsetting currency transactions across borders to reduce costs. The group focuses primarily on private clients and small and midsize enterprises, but it is building out its platform business aimed at providing its services as a backend solution to banks. By operating local accounts in each jurisdiction Wise sends money to or receives money from, this fintech offers faster and cheaper currency transfer services than incumbents (banks). Wise has started to broaden its product offering, issuing its clients debit cards and allowing customers to invest funds in various asset management products.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.